Iain De Havilland is CEO of NADclinic Group and a pioneer in modern lifestyle medicine. Over the past decade, he has helped evolve NAD+ IV therapy from an addiction-based treatment into a globally adopted longevity and performance protocol, while leading the international standardisation of premium NAD+ injectables and advanced longevity therapeutics.

 

Under his leadership, NADclinic Group has grown into  the world’s leading manufacturer of premium NAD+ therapeutics, integrating next-generation diagnostics and biomarker intelligence to deliver scalable, outcome-based longevity solutions.

 

Known for his direct, science-first approach, Iain works closely with clinicians, innovators, and performance-driven individuals, as well as some of the world’s leading hospitality and elite fitness organisations, to build solutions grounded in proof, precision, and performance.